What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Top results for memantine
21. Memantine Accord
22. Randomised controlled trial: Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine
23. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. (Abstract)
24. Memantine in Combination with Cholinesterase Inhibitors for Alzheimer?s Disease: Clinical Effectiveness and Safety
25. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease
26. Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands Full Text available with Trip Pro
28. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. (Abstract)
2012 Lancet Controlled trial quality: predicted high
29. Donepezil and memantine for moderate-to-severe Alzheimer's disease. Full Text available with Trip Pro
2012 NEJM Controlled trial quality: predicted high
What is the impact of the responder analyses calculated post hoc by Merz and submitted to the G-BA in the fourth quarter of 2010